Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Markets for Neurostimulation Products

This article was originally published in Start Up

Executive Summary

According to "US Markets for Neurostimulation Products," a report published in November 2006 by the Medtech Insight division of Windhover Information Inc., neurostimulation devices have the potential to address several clinical applications in which patient populations number in the millions: chronic pain affects five million people in the US; chronic depression four million, and chronic migraine headache two million. Based on projects currently in development, Medtech Insight lists 18 separate clinical indications for neurostimulation, from Alzheimer's disease to sleep apnea.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel